Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04990609 · ClinicalTrials.gov registry record · Phase 2

EUS-RFA PANCARDINAL-1 Trial

A Phase 2 study of Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by The University of Texas Health Science Center, Houston.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
1
Study location

NCT04990609 is a Phase 2 study of Pancreatic Ductal Adenocarcinoma (PDAC) that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 60 participants, below the 293-participant average among 16 other Pancreatic Ductal Adenocarcinoma (PDAC) trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04990609, a Phase 2 study of Pancreatic Ductal Adenocarcinoma (PDAC), is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) plus standard-of-care neoadjuvant chemotherapy (NAC) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound (EUS) radiofrequency ablation (RFA) and neoadjuvant chemotherapy (NAC) will be performed before tumor resection surgery, with the goal of shrinking a tumor or stopping the spread of cancer so that surgery might be less invasive and more effective.

Conditions Studied

Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

  • DRUG Neoadjuvant Chemotherapy (NAC)
  • DEVICE Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA)

Study Locations (1)

Texas

  • Memorial Hermann Hospital - Houston

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2021-08-13
Est. Completion 2028-05-30
Phase Phase 2

Sponsor

The University of Texas Health Science Center, Houston

732 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04990609

The ClinicalTrials.gov registry entry for NCT04990609 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 16 other Pancreatic Ductal Adenocarcinoma (PDAC) trials with a reported enrollment target (80% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma (PDAC) appearing as the primary indexed condition, and to 2 interventions - of which Neoadjuvant Chemotherapy (NAC) is the first listed.

NCT04990609 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04990609 about?

NCT04990609 is a clinical study titled "EUS-RFA PANCARDINAL-1 Trial". The objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) plus standard-of-care neoadjuvant chemotherapy (NAC) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound (EUS)...

What is the current status of trial NCT04990609?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2021-08-13. Estimated completion is 2028-05-30.

What conditions does trial NCT04990609 study?

This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma (PDAC).

What interventions are being tested in trial NCT04990609?

The interventions under investigation include: Neoadjuvant Chemotherapy (NAC) (DRUG), Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA) (DEVICE).

Who is sponsoring clinical trial NCT04990609?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04990609 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Ductal Adenocarcinoma (PDAC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Ductal Adenocarcinoma (PDAC)

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.